DOV Pharmaceutical

We are a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system, cardiovascular and urological disorders. We have five product candidates in clinical trials addressing therapeutic indications with significant unmet needs. Our product candidate for insomnia is currently in Phase III clinical trials and our product candidates for the treatment of anxiety disorders and pain are in Phase II clinical trials. Our product candidates for the treatment of insomnia, anxiety and pain have demonstrated positive results in Phase II clinical trials. Our product candidate for the treatment of angina and hypertension is currently in Phase I clinical trials and we intend to initiate Phase III clinical trials by the end of 2002. Our product candidate for the treatment of depression is currently in Phase I clinical trials. We also have four compounds in preclinical development for the potential treatment of depression, panic disorders, Parkinson's disease, attention deficit disorder and stress incontinence.

Our core scientific expertise is in the cellular and molecular pharmacology underlying central nervous system and cardiovascular disorders. Our senior management team has substantial experience in drug discovery and development. During their careers, they have participated in the discovery and development of ten new drugs that have been successfully brought to market. To enhance our drug development and commercialization efforts, we have established collaborative agreements with Elan Corporation, plc and Biovail Laboratories Incorporated, and have sublicensed our product candidate for the treatment of insomnia to Neurocrine Biosciences, Inc.

Contact Details: 433 Hackensack Avenue Hackensack NJ 07601 United States of America Tel: Fax: Email: WWW: www.dovpharm.com/

Loading...

Recent Publications by DOV Pharmaceutical:
Designing new treatments for depression and anxiety. Depression and anxiety are disabling disorders that affect many...	13th June, 2008	DOV Pharmaceutical	IDrugs. 2008 Mar;11(3):189-97.
The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. Selective inhibitors of biogenic amine (e.g., serotonin, norepinephrine,...	25th March, 2008	Department of Preclinical Pharmacology, DOV Pharmaceutical, Inc., 150	J Pharmacol Exp Ther. 2008 Mar;324(3):1111-26. Epub 2007 Dec 18. DOI Direct Link
AMPA receptors: a target for novel antidepressants? Depression and anxiety are disabling disorders that affect many...	1st March, 2008	DOV Pharmaceutical, Inc., Somerset, New Jersey 08873, USA.	Biol Psychiatry. 2008 Feb 15;63(4):347-8. DOI Direct Link
Pharmacokinetics, disposition, and metabolism of bicifadine in humans. Bicifadine [DOV 220,075;...	22nd February, 2008	DOV Pharmaceutical, Inc., 150 Pierce St., Somerset, NJ 08873, USA.	Drug Metab Dispos. 2008 Feb;36(2):252-9. Epub 2007 Nov 8. DOI Direct Link
Triple uptake inhibitors: therapeutic potential in depression and beyond. Drugs that interfere with the uptake and/or metabolism of biogenic amines...	15th September, 2007	DOV Pharmaceutical, Inc.,	Expert Opin Investig Drugs. 2007 Sep;16(9):1365-77. DOI Direct Link
→View more DOV Pharmaceutical research publications.

Press Releases on DOV Pharmaceutical:
Neurocrine Biosciences Reports Second Quarter 2008 Results	30th July, 2008	Neurocrine Biosciences, Inc.	SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended June 30, 2008. For the second quarter of 2008,

BioNews Results for DOV Pharmaceutical:
Despite Omeros Flop, Trius and Other Biotech IPO Hopefuls Might Fare Better	Cafepharma:  Nov 9 2009 8:03PM Matching: dov pharmaceutical
Foamix Expands International Patent Protection for its Emollient Foam Platform	PR Newswire:  Nov 8 2009 5:58PM Matching: dov pharmaceutical
Foamix Expands International Patent Protection for its Emollient Foam Platform	KOTA Territory News:  Nov 4 2009 3:34PM Matching: dov pharmaceutical
Foamix Expands International Patent Protection for its Emollient Foam Platform	Genetic Engineering News:  Nov 4 2009 3:58PM Matching: dov pharmaceutical
Foamix Expands International Patent Protection for its Emollient Foam Platform	Yahoo! Canada:  Nov 4 2009 8:50PM Matching: dov pharmaceutical
Promote your company here: BioNewsCast - Press Release Distribution	→View more DOV Pharmaceutical news.

DOV Pharmaceutical Clinical Trials:
Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain

DOV Pharmaceutical Patents:
US Patent No.	Title
7098230	(-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
7098229	(+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
7094799	Polymorphs of bicifadine hydrochloride
7081471	(-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
6716868	(-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
→View more DOV Pharmaceutical patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 535 times since April 2007, the link to the organisation's website has been followed 82 times

Search for more companies in Hackensack

Search for more companies in NJ

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for DOV Pharmaceutical